2-(4-chloro-6-(3,4,5-trimethoxyphenylamino)-1,3,5-triazin-2-ylamino)-N-cyclopropylbenzamide | 1448791-12-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(4-chloro-6-(3,4,5-trimethoxyphenylamino)-1,3,5-triazin-2-ylamino)-N-cyclopropylbenzamide
• CAS: 1448791-12-5
• 化学式: C₂₂H₂₃ClN₆O₄
• 分子量: 470.915
• InChiKey: UDLZTBPDACGGOV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.93
• 重原子数：
  33.0
• 可旋转键数：
  9.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  119.52
• 氢给体数：
  3.0
• 氢受体数：
  9.0

反应信息

• 作为反应物：
  描述：

  2-(4-chloro-6-(3,4,5-trimethoxyphenylamino)-1,3,5-triazin-2-ylamino)-N-cyclopropylbenzamide 在 palladium 10% on activated carbon 、 氢气 、 三乙胺 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 以82%的产率得到N-cyclopropyl-2-(4-(3,4,5-trimethoxyphenylamino)-1,3,5-triazin-2-ylamino)benzamide
  参考文献：
  名称：

  Synthesis of novel diarylamino-1,3,5-triazine derivatives as FAK inhibitors with anti-angiogenic activity

  摘要：

  We report herein the synthesis of novel diarylamino-1,3,5-triazine derivatives as FAR (focal adhesion kinase) inhibitors and the evaluation of their anti-angiogenic activity on HUVEC cells. Generally, the effects of these compounds on endothelial cells could be correlated with their kinase inhibitory activity. The most efficient compounds displayed inhibition of viability against HUVEC cells in the micromolar range, as observed with TAE-226, which was designed by Novartis Pharma AG. X-ray crystallographic analysis of the co-crystal structure for compound 34 revealed that the mode of interaction with the FAR kinase domain is highly similar to that observed in the complex of TAE-226. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.06.038
• 作为产物：
  描述：

  3,4,5-三甲氧基苯胺 在 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 为溶剂， 生成 2-(4-chloro-6-(3,4,5-trimethoxyphenylamino)-1,3,5-triazin-2-ylamino)-N-cyclopropylbenzamide
  参考文献：
  名称：

  Synthesis of novel diarylamino-1,3,5-triazine derivatives as FAK inhibitors with anti-angiogenic activity

  摘要：

  We report herein the synthesis of novel diarylamino-1,3,5-triazine derivatives as FAR (focal adhesion kinase) inhibitors and the evaluation of their anti-angiogenic activity on HUVEC cells. Generally, the effects of these compounds on endothelial cells could be correlated with their kinase inhibitory activity. The most efficient compounds displayed inhibition of viability against HUVEC cells in the micromolar range, as observed with TAE-226, which was designed by Novartis Pharma AG. X-ray crystallographic analysis of the co-crystal structure for compound 34 revealed that the mode of interaction with the FAR kinase domain is highly similar to that observed in the complex of TAE-226. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.06.038